Aisling Capital Team

Aisling Capital is led by a group of investment professionals with diverse backgrounds in
industry, science and finance.

The team’s complementary backgrounds give Aisling Capital unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify investment opportunities. In working with our portfolio companies, the principals of Aisling Capital seek to provide the financing, relationships, and guidance needed to build highly successful companies.

  • Steven A. Elms

    Managing Partner

    Steven A. Elms

    Mr. Elms joined Aisling in July of 2000 and currently serves as one of the Managing Partners. Previously, he was a Principal in the Life Sciences Investment Banking Group of H&Q. During his five years at H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group.

    Mr. Elms currently serves as a director of ADMA Biologics, Advion BioSciences, Cidara Therapeutics, EarLens, LENSAR, Loxo Oncology, Pernix Therapeutics and TRIA Beauty. Previously he served as a director of Archimica Cooperatief, Ambit Biosciences, Avera Pharmaceuticals, Bioenvision, CeNeRx BioPharma, NextWave Pharmaceuticals, Novazyme Pharmaceuticals and Scerene Healthcare and was Chairman of the Board of Adams Respiratory Therapeutics, MAP Pharmaceuticals and Oculex Pharmaceuticals.

    Mr. Elms received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Human Biology from Stanford University.

  • Andrew Schiff, MD

    Managing Partner

    Andrew Schiff, MD

    Dr. Schiff joined Aisling in September of 1999 and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of Agile Therapeutics, ARMGO Pharma, PowerVision and ZELTIQ Aesthetics. Prior Board service includes Adams Respiratory Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, CardioKine, Cempra, Miramar Labs, Myogen, SkinMedica, Sirion Therapeutics, TransEnterix and Quintiles (Board observer). He is a longtime supporter and Board member of the Visiting Nurse Service of New York.

    Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his B.S. with honors in Neuroscience from Brown University.

  • Dennis J. Purcell

    Founder and Senior Advisor

    Dennis J. Purcell

    Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

    Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

    Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association and the Irvington Institute. He also serves on the Board of L.E.K. Consulting.

    Mr. Purcell received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware.

  • Dov A. Goldstein, MD


    Dov A. Goldstein, MD

    Dr. Goldstein joined Aisling in 2006 and currently serves as a Partner. He is the acting Chief Financial Officer of Loxo Oncology, an Aisling Capital III portfolio company. Prior to joining Aisling, Dr. Goldstein served as Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals for five years, up until its acquisition by Pfizer. While at Vicuron Pharmaceuticals, he raised over $250 million in an IPO, PIPE, follow-on and block trade transactions. He led the valuation and finance due diligence for the merger with Biosearch Italia (Nuovo mercato: BIO.MI), the first U.S. and Italian public-to-public company merger. He also ran the investor relations and press relations efforts for the company. Prior to Vicuron, Dr. Goldstein was Director of Venture Analysis at Healthcare Ventures. He also completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital.

    Dr. Goldstein currently serves as a director of ADMA Biologics, Cempra and Esperion Therapeutics. Previously, he served as a director of Durata Therapeutics (acquired by Actavis), Loxo Oncology and Topaz Pharmaceuticals (acquired by Sanofi) and on other private company Boards.

    Dr. Goldstein received his M.D. from Yale School of Medicine. He received his M.B.A. from Columbia Business School and his B.S. with honors from Stanford University.

  • Aftab R. Kherani, MD


    Aftab R. Kherani, MD

    Dr. Kherani joined Aisling in 2008 and currently serves as a Partner. Previously, Dr. Kherani was an Engagement Manager for two years at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices. Prior to McKinsey, Dr. Kherani was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He also completed a two-year post-doctoral research fellowship investigating treatments for heart failure and arrhythmia at Columbia University, College of Physicians & Surgeons. While at Columbia, he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of New York Presbyterian Hospital.

    Dr. Kherani currently serves as a director of TransEnterix and as a Board observer at ARMGO Pharma, EarLens, Loxo Oncology, Syros Pharmaceuticals and T2 Biosystems.

    Dr. Kherani received his M.D. from Duke University, where he was a Howard Hughes Medical Institute Research Fellowship recipient. He also received his B.S. in Biology and A.B. in Economics from Duke, both magna cum laude, graduating Phi Beta Kappa.

  • Stacey D. Seltzer


    Stacey D. Seltzer

    Ms. Seltzer joined Aisling in 2008 and currently serves as a Partner. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.

    Ms. Seltzer serves as a director of Allergen Research Corporation and Miramar Labs. Previously, she served as a Board observer for Agile Therapeutics, Durata Therapeutics and ZELTIQ Aesthetics. She also acted as the Aisling representative for its investment in Precision Dermatology and was closely involved in Aisling’s investments in Cytos, Dermira and PowerVision.

    Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her M.S. and B.S. from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.

  • Anthony Y. Sun, MD


    Anthony Y. Sun, MD

    Dr. Sun joined Aisling in 2002 and currently serves as a Partner. Previously, Dr. Sun was an Adjunct Instructor of Medicine at the Hospital of the University of Pennsylvania for two years.

    Dr. Sun currently serves as a director of Versartis and a Board observer for Pharmaron. Previously he served as a director of CeNeRx BioPharma, Dynova Laboratories, HerbalScience Group, MAP Pharmaceuticals and Paratek Pharmaceuticals.

    Dr. Sun received his M.D. from Temple University School of Medicine with A.O.A. honors. He received his M.B.A. from The Wharton School at the University of Pennsylvania and his B.S. in Electrical Engineering from Cornell University. In addition, he was previously Board Certified in Internal Medicine.

  • Josh Bilenker, MD

    Operating Partner

    Josh Bilenker, MD

    Dr. Bilenker joined Aisling in 2006 and currently serves as an Operating Partner. He is President and Chief Executive Officer of Loxo Oncology, an Aisling Capital III portfolio company. Prior to Aisling, Dr. Bilenker served as a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties.

    Dr. Bilenker currently serves as a director of LENSAR, Loxo Oncology, Roka Bioscience, T2 Biosystems and ViewRay. Previously he served as a Board observer at Aragon Pharmaceuticals. He is also a Board Member of the NCCN Foundation and of BioEnterprise.

    Dr. Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.

  • Lloyd E. Appel

    Chief Financial Officer and Chief Compliance Officer

    Lloyd E. Appel

    Mr. Appel joined Aisling in March 2008 and serves as Chief Financial Officer. For four years prior to joining Aisling, he served as the CFO of two small hedge funds. Additionally, he was the Controller of ING Furman Selz Asset Management, a firm with approximately $20 billion under management in numerous investment strategies. Mr. Appel spent nearly eight years at BDO Seidman, LLP, a large national public accounting firm, where he attained the role of Audit Manager.

    Mr. Appel received his B.A. in Accounting and Economics from Queens College, awarded magna cum laude. He is a Certified Public Accountant licensed in the State of New York and a Certified Financial Analyst.

  • Robert J. Wenzel


    Robert J. Wenzel

    Mr. Wenzel joined Aisling in June 2008 and serves as the Controller. For twelve years prior, he was Vice President at Lazard Alternative Investments (Lazard) where he supervised the financial reporting of several domestic and offshore private equity funds. Prior to joining Lazard, Mr. Wenzel began his career at Eisner & Lubin, LLP, a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele, attaining the role of Senior Accountant.

    Mr. Wenzel received his B.B.A. in Accounting from Baruch College in 1993 and holds his Certified Public Accountant license in the state of New York. He is also a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.

  • Jan Hoerrner

    Director of Investor Relations and Marketing

    Jan Hoerrner

    Ms. Hoerrner joined Aisling in October of 2000 and serves as the Director of Investor Relations and Marketing at Aisling Capital. In this role, Ms. Hoerrner manages relationships with over eighty limited partners, and is a key contributor in Aisling’s fundraising and marketing efforts. Previously, Ms. Hoerrner was with H&Q, a leading underwriter and strategic advisor to the biotechnology industry. During her five years at H&Q, Ms. Hoerrner was responsible for coordinating their Healthcare Conferences and also served as Administrative Manager for the New York office.

    Ms. Hoerrner received her B.S. in Business Administration from Bryant University.

  • Cecilia Sun


    Cecilia Sun

    Ms. Sun serves as an Analyst at Aisling Capital. Previously, Ms. Sun was an Analyst in the Leveraged Finance Group at Credit Suisse in New York.

    Ms. Sun is a graduate of the Roy and Diana Vagelos Program in Life Sciences & Management at the University of Pennsylvania. She holds a B.S. in Economics, with concentrations in Finance and Healthcare Management and a B.A. in Biology with distinction, awarded summa cum laude.

  • Ayman Sabi

    Venture Partner

    Ayman Sabi

    Mr. Sabi is an independent consultant serving as a Venture Partner at Aisling Capital. He is the founder of SABi Medical Group, B.V., and a seasoned entrepreneur with almost 30 years of fiscal, strategic and operational leadership. Mr. Sabi founded and led SABi Ventures and SABi Trading and Contracting, Inc., which focused on international trade, retail and real estate. Formerly, Mr. Sabi was CEO and/or Director of White House / Black Market, Inc. (acquired by Chico’s, Inc. in 2000), Roadhouse Grill, Inc. (IPO 1996 NASDAQ), New Global, LLC (shopping centers, sold 2002) and National Retail Group, Inc.

    Mr. Sabi has a B.A. from North Carolina State University.